- First patient dosed in Phase 1/2 trial for lead candidate ATR 1072 targeting PRKAG2 syndrome.
- Study to enroll ~37 participants with initial proof-of-concept data expected in H2 2027.
?? Positive AI Sentiment (+2.0 / 10)
Ticker archive · $RNA
$RNA Filing Signals & Market Reactions
Delayed, SEO-crawlable recaps of AI-scored catalysts for $RNA — including observed post-filing price moves. Live streaming stays exclusive to VIP.